introduct
viruslik
particl
vlp
vaccin
face
signific
challeng
translat
laboratori
model
routin
clinic
administr
vlp
vaccin
thrive
readili
adopt
vaccin
schedul
other
restrain
regulatori
obstacl
proprietari
limit
find
nich
amongst
crowd
vaccin
market
often
necess
supplant
exist
vaccin
regimen
possess
immedi
obstacl
develop
vlp
vaccin
despit
preclin
advantag
identifi
competit
novelti
adapt
formul
compat
may
prove
invalu
help
place
vlp
vaccin
forefront
vaccin
technolog
area
cover
purpos
review
outlin
divers
vlp
vaccin
vlpspecif
immun
respons
explor
modern
formul
deliveri
techniqu
enhanc
clinic
relev
overal
success
vlp
vaccin
expert
commentari
role
format
scienc
emphasi
divers
immun
respons
induc
vlp
underrepres
amongst
clinic
trial
vlp
vaccin
har
divers
particularli
use
combin
select
excipi
adjuv
paramount
develop
vlp
vaccin
articl
histori
viruslik
particl
vlp
type
subunit
vaccin
base
virusderiv
protein
assembl
form
particl
vlp
hold
sever
advantag
particul
subunit
vaccin
includ
morpholog
resembl
parent
viru
highli
repetit
immunogen
surfac
structur
retent
cell
uptak
immun
process
pathway
associ
parent
viru
vlp
nonpathogen
devoid
intact
viru
genom
incap
infect
replic
noninfecti
natur
vlp
significantli
improv
safeti
profil
liveattenu
vaccin
also
possess
advantag
compar
form
subunit
kill
particul
vaccin
commerci
success
vlp
vaccin
includ
hepat
b
viru
hbv
vlp
recombivax
hb
merck
engerixb
glaxosmithklin
elovac
b
human
biolog
institut
genevac
b
serum
institut
shanvac
b
shantha
biotechn
hepat
e
viru
hev
vlp
hecolin
innovax
human
papillomaviru
hpv
vlp
includ
gardasil
merck
cervarix
glaxosmithklin
vlp
vaccin
current
investig
clinic
trial
includ
influenza
viru
iav
vlp
chikungunya
viru
vlp
human
cytomegaloviru
hcmv
vlp
human
noroviru
hunv
vlp
recent
current
vlp
clinic
trial
regist
unit
state
america
european
union
summar
tabl
vlp
bulk
express
bioreactor
cultur
util
advanc
vitro
protein
express
system
produc
vaccinegrad
vlp
suitabl
clinic
administr
manufactur
vlp
also
includ
addit
process
step
disassembl
reassembl
vlp
manufactur
hpv
vlp
util
disassembl
reassembl
improv
vlp
morpholog
stabil
similarli
manufactur
vlp
includ
method
differ
vlp
express
system
applic
vlp
disassembl
reassembl
explor
recent
review
compat
commerci
upscal
technolog
gmp
product
minim
postproduct
manipul
modif
support
largescal
use
vlp
vaccin
howev
vlp
vaccin
struggl
translat
laboratori
research
develop
clinic
trial
routin
public
access
open
access
molecular
genet
compon
deriv
constitu
may
place
limit
commerci
specif
vlp
vaccin
may
circumv
tactic
use
proprietari
modif
util
vaccin
constitu
within
composit
formul
develop
vlp
vaccin
challeng
issu
stabil
longev
may
allevi
formul
excipi
vaccin
addit
facilit
vaccin
distribut
storag
purpos
review
explor
challeng
translat
negativesens
rna
virus
human
parainfluenza
viru
type
varieti
observ
vlp
size
rang
bacteriophag
vlp
around
nm
diamet
hpv
vlp
around
nm
influenza
vlp
around
nm
vlp
also
vari
structur
complex
illustr
figur
includ
monolay
vlp
hbv
vlp
form
hbv
surfac
antigen
hbsag
hbv
core
antigen
hbcag
multilay
vlp
rotaviru
vlp
vlp
encapsul
within
phospholipid
bilay
envelop
resembl
parent
viru
hiv
sendai
viru
vlp
envelop
also
form
primari
particl
structur
vlp
recombinantli
express
viru
envelopestabil
protein
embed
within
membran
iav
virosom
vlp
compat
format
polyval
mosaic
vlp
deriv
multipl
viru
strain
increas
divers
vlp
vaccin
beyond
varieti
parent
virus
increas
complex
polyval
mosaic
vlp
may
requir
postproduct
manipul
facilit
stabl
particl
format
addit
facilit
develop
complex
vlp
vaccin
construct
introduct
postproduct
manipul
also
demonstr
improv
consist
stabil
standard
structur
vlp
vaccin
divers
vlp
also
character
base
varieti
diseas
vaccin
develop
prevent
treat
includ
vlp
vaccin
develop
human
veterinari
patholog
exampl
includ
hbv
hbcag
core
particlebas
vaccin
cancer
adenoviru
vlpbase
vaccin
placent
malaria
vlpbase
vaccin
leishmania
infect
select
recent
develop
investig
novel
vlp
vaccin
provid
tabl
vlp
produc
use
varieti
express
system
usual
involv
vlp
assembl
spontan
polymer
upon
express
viru
protein
constitu
vlp
express
cell
deriv
bacteria
yeast
insect
mammal
cellfre
express
system
live
organ
silkworm
pupa
variou
plant
select
appropri
express
system
import
express
system
differ
efficaci
express
specif
vlp
posttransl
modif
eg
phosphoryl
glycosyl
potenti
contamin
biolog
compat
zoonot
virus
protein
express
product
vlp
highli
amen
modif
substitut
strainspecif
amino
acid
sequenc
insert
foreign
peptid
sequenc
protein
manipul
process
facilit
engin
recombin
chimer
vlp
contain
xenogen
antigen
induc
immun
respons
target
parent
viru
vlp
also
present
selfantigen
immunogen
context
particularli
use
immunotherapeut
vaccin
cancer
divers
rang
applic
type
modif
investig
prophylact
therapeut
variou
condit
includ
protect
infect
organ
autoimmun
inflammatori
diseas
antitumor
immunotherapi
chimer
vlp
investig
potenti
therapi
condit
usual
associ
vaccin
atherosclerosi
type
ii
diabet
mellitu
nicotin
addict
vlp
vaccin
util
chemic
conjug
incorpor
antigen
sequenc
oppos
recombin
insert
vlp
serv
effect
immunogen
scaffold
chemic
conjug
compat
broad
rang
conjug
chemistri
applic
chemic
conjug
vlp
comprehens
review
recent
articl
howev
worth
note
introduc
uniqu
form
chemic
conjug
may
provid
proprietari
claim
method
involv
vlp
vaccin
alreadi
public
domain
vlp
form
subunit
vaccin
induc
characterist
immun
respons
share
amongst
exogen
antigen
vlp
taken
cell
nonspecif
pathway
phagocytosi
macropinocytosi
vlp
also
util
special
uptak
pathway
inherit
parent
viru
gener
proteinbas
subunit
vaccin
like
vlp
intern
antigenpres
cell
apc
digest
within
phagolysosom
result
antigen
peptid
present
load
major
histocompat
complex
mhc
ii
molecul
helper
cell
h
cell
h
cell
recogn
epitop
present
mhcii
specif
cell
receptor
tcr
activ
depend
strength
interact
addit
degre
signal
costimulatori
receptor
cytokin
addit
signal
usual
suppli
apc
activ
increas
present
costimulatori
receptor
releas
cytokin
respons
varieti
stimulatori
signal
stimulatori
signal
correspond
activ
pattern
recognit
receptor
prr
tolllik
receptor
tlr
nodlik
receptor
nlr
receptor
rlr
recogn
specif
pathogenassoci
molecular
pattern
pamp
damageassoci
molecular
pattern
damp
vlp
vaccin
usual
contain
minim
neglig
amount
stimulatori
molecul
signal
instead
induc
vaccin
adjuv
manipul
select
target
specif
apc
target
cell
popul
may
effect
mean
develop
novel
proprietari
vlp
vaccin
chemic
conjug
receptor
ligand
onto
surfac
compat
vlp
promot
bind
uptak
cell
express
correspond
receptor
primari
vlp
uptak
process
pathway
continu
unperturb
type
modif
may
particular
effect
target
specif
apc
popul
desir
induct
specif
type
immun
respons
exampl
chemic
conjug
mannosidebas
saccharid
surfac
rabbit
hemorrhag
diseas
viru
rhdv
vlp
select
target
mannos
receptor
express
surfac
apc
induc
increas
uptak
alter
antigen
crosspresent
murin
dendrit
cell
chemic
conjug
unmethyl
cpg
oligonucleotid
surfac
rhdv
vlp
also
investig
target
uptak
receptor
similarli
coat
hiv
vlp
phosphatidylserinelac
liposom
enhanc
uptak
macrophag
mimick
apoptot
bodi
although
immun
respons
vlp
may
gener
due
similar
share
subunit
vaccin
uniqu
compon
vlpinduc
immun
respons
pathway
uptak
vlp
apc
vari
depend
size
morpholog
vlp
includ
potenti
retent
receptor
bind
motif
particl
smaller
nm
noroviru
p
particl
drain
directli
vaccin
site
lymph
pore
fenestr
lymphat
vessel
traffick
molecul
within
lymphat
likewis
size
depend
solubl
protein
smaller
kda
nm
transport
special
small
antigen
conduit
vlp
larger
nm
mani
instead
transport
passiv
lymph
node
bound
surfac
myeloid
immun
cell
vlp
larger
nm
drain
directli
fenestr
pore
lymph
instead
requir
activ
transport
follow
intern
apc
vaccin
site
dendrit
cell
dc
macrophag
b
cell
uptak
viru
antigen
antigen
present
cell
occur
multipl
pathway
includ
phagocytosi
macropinocytosi
caveolaemedi
uptak
clathrinmedi
uptak
clathrin
noncaveolaemedi
uptak
vlp
identifi
util
similar
repertoir
uptak
pathway
includ
phagocytosi
sizedepend
macropinocytosi
clathrindepend
independ
form
receptormedi
endocytosi
retent
receptormedi
endocytosi
indic
vlp
inherit
function
receptor
bind
domain
compat
correspond
uptak
pathway
deriv
parent
viru
mechan
receptormedi
uptak
also
introduc
vlp
postexpress
modif
chemic
conjug
superantigen
hbv
vlp
intern
mhcii
molecul
chemic
conjug
transferrin
vlp
intern
transferrin
receptor
upregul
cancer
cell
nonspecif
uptak
apc
subject
vlp
standard
compon
exogen
antigen
process
pathway
includ
lysosom
fusion
enzymat
digest
mhcii
load
antigen
present
figur
parent
virus
vlp
intern
pathway
engag
addit
mechan
progress
toward
viru
replic
includ
capsid
disassembl
uncoat
export
viru
genom
materi
disrupt
vesicular
fusion
retent
intracellular
process
mechan
resembl
util
parent
virus
investig
vlp
remain
unclear
whether
vlp
univers
mimic
intracellular
process
parent
viru
vlp
retain
access
crosspresent
pathway
facilit
present
antigen
mhc
class
mhci
induct
cellmedi
cytotox
immun
respons
sever
known
mechan
crosspresent
apc
includ
antigen
escap
earli
endosom
fusion
endosom
endoplast
vlp
intern
process
varieti
intracellular
pathway
vlp
intern
nonspecif
pathway
phagocytosi
macropinocytosi
process
peptid
present
mhcii
exogen
antigen
b
vlp
also
util
crosspresent
pathway
facilit
present
peptid
mhci
c
influenza
vlp
exampl
influenza
virosom
intern
receptormedi
endocytosi
prior
fusion
envelop
endosom
membran
jcv
vlp
thought
util
process
pathway
parent
viru
facilit
deliveri
exogen
nucleic
acid
includ
clathrindepend
endocytosi
nuclear
traffick
uncoat
capsid
within
nucleu
reticulum
recycl
mhci
receptor
cell
surfac
rhdv
vlp
known
util
mhci
receptor
recycl
pathway
crosspresent
figur
b
addit
exampl
vlp
known
induc
crosspresent
antigen
includ
vlp
deriv
hbv
hepat
c
viru
hcv
hpv
papaya
mosaic
viru
parvoviru
abil
induc
crosspresent
import
cellmedi
cytotox
immun
respons
primari
desir
outcom
vlp
vaccin
retent
receptormedi
intern
vlp
illustr
mechan
uptak
parent
viru
autonom
independ
integr
complet
virion
vlp
deriv
influenza
b
virus
prime
exampl
process
influenza
vlp
produc
sever
form
includ
envelop
vlp
form
express
influenza
matrix
protein
retrovir
gag
protein
independ
virosom
particl
without
tradit
protein
core
construct
includ
express
influenza
hemagglutinin
ha
without
neuraminidas
na
influenza
protein
crucial
induct
influenzaspecif
immun
respons
also
play
essenti
role
bud
influenza
viruslik
particl
receptormedi
endocytosi
influenza
vlp
bind
sialyl
glycoprotein
glycolipid
surfac
cell
inher
activ
ha
intern
clathrinmedi
endocytosi
figur
c
howev
altern
endocyt
pathway
also
identifi
earli
endosom
ph
lower
envelop
fuse
endosom
membran
ha
na
protein
distribut
along
intern
surfac
endosom
membran
enzymat
degrad
peptid
present
exogen
antigen
mhcii
figur
c
special
vlp
vaccin
design
deliv
genet
payload
add
complic
vlp
uptak
process
retent
abil
deliv
dnarna
requir
conserv
intracellular
process
pathway
util
parent
viru
replic
induct
altern
method
nucleic
acid
transloc
john
cunningham
viru
jcv
vlp
polyomaviru
vlp
receiv
signific
attent
abil
facilit
gene
deliveri
genet
manipul
jcv
intern
clathrindepend
endocytosi
upon
bind
undefin
plethora
receptor
molecul
known
includ
serotonin
receptor
sialic
acid
viru
coloc
endosom
along
transferin
prior
cytosol
transloc
subsequ
traffick
nuclear
pore
mediat
nterminu
capsid
protein
viru
uncoat
expos
genom
materi
within
capsid
jcv
vlp
thought
mimic
process
due
abil
deliv
dna
plasmid
nucleic
acid
nucleu
figur
vlp
demonstr
abil
deliv
nucleic
acid
like
util
similar
process
pathway
parent
viru
vlp
also
modifi
util
altern
process
pathway
primari
desir
outcom
commerci
vlp
vaccin
product
antibodi
specif
vlp
parent
viru
antivlp
antibodi
produc
vaccin
correspondingli
neutral
parent
viru
protect
infect
product
antivlp
antibodi
involv
activ
humor
immun
respons
b
cell
specif
recogn
vlp
surfac
domain
b
cell
receptor
bcr
bind
intern
vlp
bind
vlp
bcr
provid
stimulatori
signal
prime
b
cell
activ
vlp
consist
structur
ident
capsid
protein
arrang
repetit
quasicrystallin
pattern
crosslink
multipl
bcr
provid
stimulatori
advantag
type
subunit
vaccin
crosslink
bcr
import
induc
robust
humor
respons
b
cell
ignor
monomer
solubl
antigen
potent
stimul
bcr
crosslink
overrid
inher
tolerogen
mechan
activ
unrespons
anerg
b
cell
highli
repetit
structur
also
promot
bind
lowaffin
bcr
multival
highavid
interact
antigen
prime
b
cell
receiv
addit
activ
signal
induc
pamp
deliv
vlp
vaccin
signal
usual
provid
vaccin
adjuv
may
also
induc
virusassoci
expressionderiv
endogen
molecul
associ
vlp
vlpderiv
antigen
present
h
cell
load
mhcii
induc
cytokin
costimulatori
receptor
signal
h
cell
continu
b
cell
activ
activ
b
cell
initi
becom
plasmablast
transient
extrafollicular
activ
state
provid
immedi
antibodi
product
plasmablast
migrat
follicular
region
lymph
node
form
germin
center
special
region
activ
b
cell
prolifer
plasmablast
within
germin
center
affin
matur
immunoglobulin
class
switch
guid
signal
follicular
helper
fh
cell
special
fh
cell
guidanc
result
develop
highaffin
antibodyproduc
plasma
cell
longliv
memori
b
cell
rapid
cellindepend
activ
also
induc
margin
zone
b
cell
cell
provid
altern
pathway
activ
antibodi
product
predomin
follicular
b
cell
popul
vlp
identifi
util
altern
form
b
cell
activ
product
antivlp
antibodi
investig
character
amongst
broad
rang
vlp
process
influenc
variou
vaccin
compon
constitu
even
unexpect
molecul
deriv
vlp
express
system
exampl
presenc
bacteri
rna
pack
insid
vlp
play
role
induct
antibodi
mice
antibodi
human
vlp
also
induc
product
iga
class
antibodi
immunocompet
mice
immun
intranas
rout
h
celldefici
mice
requir
subcutan
rather
intranas
vaccin
induc
robust
iga
product
tcell
independ
b
cell
activ
simul
singlestrand
rna
endosom
also
identifi
crucial
induct
iga
antibodi
vlp
mice
indic
import
endogen
bacteri
rna
present
vlp
induct
antihpv
vlp
antibodi
also
extens
studi
although
product
secretori
iga
antibodi
desir
protect
viral
infect
mucos
surfac
predomin
antibodi
class
found
secret
femal
genit
tract
follow
vaccin
hpv
vlp
igg
presenc
igg
secret
may
due
transud
serum
activ
transport
local
product
mucosa
may
possibl
vaccin
hpv
vlp
induc
product
igg
iga
antibodi
serum
cervic
secret
human
serum
titer
antihpv
antibodi
may
initi
declin
postvaccin
level
plateau
remain
stabl
provid
prolong
immun
induct
potent
humor
immun
respons
subsequ
product
antivlp
antibodi
primari
desir
outcom
commerci
vlp
vaccin
increas
appreci
role
vaccineinduc
cellmedi
immun
measur
antivlp
titer
provid
import
indic
vaccin
efficaci
respect
neutral
viru
challeng
cellmedi
immun
respons
also
play
import
role
antiviru
immun
defens
activ
cellmedi
immun
respons
also
primari
desir
outcom
vlp
vaccin
particularli
chimer
modifi
vlp
vaccin
target
nonviru
patholog
potent
cellmedi
respons
vlp
vaccin
depend
upon
crosspresent
vlpderiv
antigen
mhci
cytotox
c
cell
recogn
mhci
antigen
complex
tcr
becom
prime
activ
antigenprim
c
cell
requir
addit
signal
activ
includ
interact
costimulatori
receptor
cytokin
h
cell
mani
vlp
may
capabl
crosspresent
may
effect
induc
crosspresent
due
uptak
process
pathway
inherit
parent
viru
induct
potent
cellmedi
immun
respons
particularli
import
immunotherapeut
cancer
vaccin
tumor
cellspecif
antibodi
enhanc
inher
cytotox
activ
natur
killer
cell
mechan
antibodydepend
cellmedi
cytotox
directli
complementdepend
cytotox
howev
mechan
tend
restrict
passiv
vaccin
monoclon
antibodi
monoclon
trastuzumab
cellmedi
immun
respons
combin
target
specif
vivo
expans
effector
cell
popul
capac
establish
prolong
memori
rhdv
vlp
particularli
effect
vector
cancer
vaccin
capabl
induc
crosspresent
vlpderiv
antigen
compat
recombin
insert
chemic
conjug
rhdv
vlp
vaccin
investig
model
hpvinfect
cervic
cancer
melanoma
lewi
lung
carcinoma
colorect
cancer
addit
exampl
vlp
induc
crosspresent
potent
cellmedi
immun
respons
includ
vlp
vlp
alphaviru
vlp
preexist
immun
form
preform
antivlp
antibodi
import
consider
vlp
vaccin
bind
antivlp
antibodi
may
interfer
normal
uptak
present
pathway
vlp
vaccin
antivlp
antibodi
may
present
unvaccin
individu
due
environment
exposur
preval
strain
parent
viru
induc
follow
vlp
vaccin
presenc
preexist
antibodi
may
decreas
efficaci
alter
immun
recognit
vlp
vaccin
also
associ
measur
enhanc
vaccin
efficaci
may
due
access
fc
receptormedi
uptak
pathway
format
antibodyvlp
complex
antigen
boost
specif
b
cell
presenc
antivlp
antibodi
also
found
observ
effect
intend
vaccin
outcom
sever
vlp
vaccin
polyomaviru
rhdv
vlp
antivlp
antibodi
present
deleteri
interfer
altern
differ
vlp
vaccin
vector
may
suitabl
solut
altern
rotaviru
adenoviru
vlp
found
enhanc
humor
cellmedi
immun
respons
target
antigen
comparison
repeat
deliveri
vlp
vector
similarli
altern
close
relat
vlp
rhdv
human
noroviru
hunv
vlp
suffici
enhanc
vaccin
immunogen
complic
aris
vlp
vaccin
induc
phenomenon
refer
carrierinduc
epitop
suppress
cie
intend
immun
respons
outcompet
strong
antivlp
respons
cie
may
prevent
mask
vlp
surfac
antigen
avoid
recognit
recombin
modif
exampl
recombin
insert
domain
hiv
hev
vlp
identifi
avoid
recognit
antihev
antibodi
formul
vaccin
refer
constitu
make
final
administr
solut
includ
vaccin
vector
adjuv
excipi
vlp
vaccin
excipi
includ
varieti
salt
compound
prepar
aqueou
solut
emuls
maintain
physic
stabil
vlp
enhanc
shelf
life
vaccin
appropri
use
buffer
limit
fluctuat
ph
protect
fluctuat
temperatur
desicc
may
provid
thermoprotect
lyoprotect
respect
formul
scienc
involv
investig
variou
compon
vaccin
differ
environment
condit
intent
formul
stabl
vaccin
product
suitabl
rout
administr
maxim
immunogen
combin
formul
compon
vlp
vaccin
prepar
state
rout
administr
outlin
figur
major
vlp
vaccin
current
market
clinic
evalu
liquid
suspens
readi
administr
place
strict
limit
vlp
vaccin
storag
distribut
safe
compliant
administr
exampl
commerci
hpv
vaccin
gardasil
merck
must
refriger
protect
light
gardasil
frozen
guidelin
use
gardasil
advis
vaccin
must
use
within
h
remov
refriger
temperatur
store
guidelin
mirror
mani
commerci
vlp
vaccin
outlin
primari
stabil
storag
distribut
challeng
formul
scienc
investig
maintain
integr
stabil
vlp
solut
larg
depend
combin
salt
buffer
chemic
compound
use
optim
buffer
ph
ionic
strength
stabil
compon
imper
develop
market
stabl
liquid
vlp
vaccin
investig
stabil
vlp
identifi
sodium
phosphatebas
buffer
superior
citrat
tri
buffer
solut
vlp
store
sodium
phosphat
buffer
remain
stabl
month
prolong
stabil
room
core
bodi
temperatur
suggest
vlp
may
suitabl
import
countri
maintain
coldchain
storag
distribut
difficult
import
consider
select
appropri
buffer
includ
compat
downstream
applic
chemic
conjug
avail
scaveng
nutrient
may
promot
growth
potenti
harm
organ
improperli
store
vaccin
variou
addit
molecul
particularli
carbohydr
trehalos
sucros
glycerol
investig
extens
vlp
vaccin
formul
addit
molecul
vaccin
formul
demonstr
enhanc
vlp
stabil
role
formul
scienc
vlp
vaccin
manufactur
includ
chemic
composit
buffer
preserv
addit
stabil
compound
maintain
intact
vlp
includ
protect
vlp
chemic
physic
instabl
enzymat
degrad
formul
also
includ
target
deliveri
compound
mucoadhes
immunogen
compon
adjuv
storag
distribut
vlp
vaccin
subsequ
rout
administr
also
import
consider
formul
scienc
critic
determin
efficaci
immunogen
vaccin
within
liquid
suspens
norwalk
viru
vlp
rotaviru
vlp
sugarbas
formul
addit
polyanion
solut
also
stabil
vlp
would
otherwis
unstabl
neutral
ph
chikungunya
viru
vlp
major
commerci
vlp
vaccin
distribut
liquid
suspens
requir
cold
chain
maintain
throughout
distribut
storag
even
stabl
cold
chain
condit
longev
vlp
limit
prolong
storag
temperatur
stabil
addit
cryopreserv
glycerol
trehalos
howev
exacerb
issu
deliv
vaccin
intact
need
develop
countri
without
reliabl
coldchain
deliveri
infrastructur
altern
storag
method
freezedri
lyophil
variabl
effect
stabil
vlp
mechan
damag
induc
ice
crystal
exposur
vari
salt
concentr
ph
chang
freez
process
may
advers
affect
integr
vlp
exposur
factor
limit
addit
specif
cryoprotect
lyoprotect
exampl
redspot
grouper
nervou
necrosi
viru
rgnnv
vlp
reportedli
retain
stabl
particl
remain
immunogen
freezedri
presenc
sorbitol
advers
affect
presenc
mannitol
vlp
murin
polyomaviru
mupyv
vlp
hbv
vlp
likewis
demonstr
capac
surviv
vari
freezedri
methodolog
spraydri
also
gain
traction
altern
vaccin
storag
mechan
avoid
potenti
mechan
damag
induc
freezedri
instead
form
dri
powder
formul
combin
nebul
dehumidif
howev
spraydri
involv
exposur
elev
temperatur
similarli
damag
thermolabil
vlp
hpv
vlp
suspend
formul
contain
mannitol
trehalos
dextran
lleucin
inositol
capabl
surviv
procedur
spraydri
vlp
store
room
temperatur
month
found
induc
high
titer
antihpv
igg
antibodi
significantli
protect
vaccin
mice
challeng
air
vacuum
dri
method
also
report
coat
microneedl
influenza
vlp
suspend
formul
contain
carboxymethylcellulos
cmc
microneedlebas
deliveri
dri
aaichi
found
induc
immun
respons
compar
intramuscular
inject
advantag
prolong
longev
storag
investig
similar
formul
prepar
strategi
differ
type
vlp
may
uncov
univers
applic
potenti
method
erad
coldchain
limit
impos
mani
vlp
vaccin
previous
describ
mani
vlp
possess
structur
molecular
featur
confer
autoimmunostimulatori
properti
properti
facilit
induct
immun
respons
vlp
without
need
adjuv
howev
use
adjuv
vlp
vaccin
may
enhanc
vaccin
immunogen
promot
activ
specif
type
immun
respons
current
licens
adjuv
use
vaccin
includ
aluminum
sulfat
salt
alum
proprietari
combin
adjuv
glaxosmithklin
glaxosmithklin
novarti
thermorevers
oilinwat
immers
montanid
mani
standard
vaccin
adjuv
may
suitabl
vlp
vaccin
gener
antivlp
antibodi
desir
outcom
adjuv
may
fail
overcom
immunotoler
induc
antitumor
immun
cancer
vaccin
formul
howev
tradit
adjuv
may
fail
novel
tlr
agonist
adjuv
success
agonist
adjuv
imiquimod
recent
approv
use
vaccin
melanoma
anoth
clinic
trial
assess
candidaci
treatment
bladder
cancer
stimul
antivir
interferon
pathway
apc
promot
activ
cell
nk
cell
use
adjuv
gardiquimod
combin
vaccin
found
induc
tumor
regress
murin
model
melanoma
human
hepatocellular
carcinoma
pancreat
cancer
agonist
adjuv
unmethyl
cpg
oligonucleotid
drawn
consider
interest
due
inher
abil
associ
vlp
similarli
presenc
nucleic
acid
downstream
ramif
immun
respons
induc
vlp
exampl
presenc
rna
insid
vlp
skew
humor
respons
induc
mice
produc
antibodi
remov
rna
result
product
antibodi
vlp
also
contain
addit
adjuv
molecul
deriv
express
system
encapsid
particl
format
recent
studi
mice
investig
use
variou
adjuv
conjunct
filoviru
vlp
vaccin
includ
agonist
adjuv
polyiclc
hiltonol
agonist
adjuv
monophospholipid
mpla
cpg
alhydrogel
polyiclc
found
induc
predominantli
h
respons
subtyp
antibodi
product
correl
protect
viru
challeng
comparison
administr
vlp
vaccin
alhydrogel
elicit
strong
h
respons
high
antibodi
titer
confer
protect
viru
challeng
studi
highlight
import
care
consid
kind
adjuv
suitabl
accompani
vlp
vaccin
immunogen
adjuv
may
necessarili
provid
desir
vaccin
outcom
vlp
vaccin
approv
clinic
use
util
variou
administr
modal
includ
vaccin
subcutan
intraderm
intramuscularli
mucos
surfac
live
attenu
vaccin
tradit
inject
subcutan
inactiv
subunit
vaccin
often
administ
intramuscularli
infant
intramuscular
inject
vaccin
tend
confer
enhanc
immunogen
subcutan
administr
modern
vaccin
deliveri
technolog
intraderm
microneedl
patch
also
investig
potenti
applic
vlp
vaccin
major
recent
clinic
trial
involv
administr
vlp
favor
intramuscular
inject
altern
rout
administr
investig
base
differenti
immunogen
differ
deliveri
site
exampl
investig
rout
administr
hunv
vlp
found
intranas
inocul
mice
induc
product
mucos
antihunv
igg
iga
antibodi
intramuscular
inject
induc
igg
product
studi
identifi
mucos
iga
suitabl
neutral
infecti
hunv
virion
render
intramuscular
inject
unsuit
administr
hunv
vlp
similar
find
identifi
regard
administr
respiratori
syncyti
viru
rsv
vlp
desir
h
respons
neutral
mucos
antibodi
cell
respons
identifi
follow
intranas
inocul
rather
intramuscular
inject
vaccin
vlp
mucos
surfac
also
requir
higher
dose
vlp
comparison
parent
administr
oral
deliveri
viruslik
particl
also
investig
altern
conveni
rout
administr
vlp
express
plantbas
system
repres
particularli
effici
mean
product
deliveri
express
edibl
plant
speci
potenti
forgo
need
vlp
purif
vaccin
formul
exampl
concept
includ
express
hbv
norwalk
viru
vlp
solanum
tuberosum
potato
lycopersicon
esculentum
tomato
plant
nicotiana
benthamiana
tobacco
also
use
effici
plant
express
system
product
vlp
hbv
vlp
purifi
n
benthamiana
capabl
withstand
simul
acid
environ
within
stomach
howev
hbcag
polypeptid
hbv
vlp
digest
expos
porcin
pepsin
protect
proteinbas
vlp
enzymat
digest
signific
hurdl
oral
deliveri
despit
promis
vaccin
rout
translat
vlp
vaccin
preclin
research
routin
clinic
administr
multifacet
task
combin
studi
stabil
formul
scienc
immunogen
clinic
vaccin
efficaci
issu
necessarili
uniqu
develop
vlp
vaccin
encompass
breadth
research
develop
necessari
bring
vaccin
candid
market
express
stabl
vlp
first
step
toward
develop
novel
vlp
vaccin
may
eventu
includ
variou
excipi
adjuv
compound
administr
form
advanc
virolog
vaccinolog
facilit
develop
novel
vlp
vaccin
seemingli
parallel
regulatori
proprietari
restrict
place
upon
new
vaccin
howev
vlp
vaccin
also
possess
unparallel
potenti
due
balanc
clinic
vaccin
efficaci
safeti
versatil
vaccin
vector
field
vlp
vaccin
continu
experi
signific
growth
past
decad
divers
vaccin
translat
vaccin
toward
routin
clinic
administr
research
focus
upon
develop
rhdv
vlp
versatil
vaccin
scaffold
particularli
immunotherapeut
vaccin
altern
treatment
option
cancer
translat
vlp
vaccin
construct
proof
concept
model
toward
clinic
administr
menial
feat
observ
correspond
shift
toward
focus
clinic
translat
amongst
colleagu
field
focal
point
discuss
highlight
process
includ
relev
translat
research
anim
model
adapt
establish
dogma
within
field
human
vaccin
establish
development
commerci
nich
conduc
advanc
novel
vaccin
throughout
rigor
clinic
trial
regulatori
approv
immun
respons
vlp
vaccin
tend
strike
desir
balanc
outcom
indic
optim
vaccin
efficaci
induct
hightit
mucos
iga
antibodi
also
maintain
almost
unparallel
vaccin
safeti
profil
inher
inabl
vlp
infect
replic
allevi
potenti
vaccin
risk
spontan
revers
pathogenesi
incomplet
inactiv
retent
abil
facilit
crosspresent
associ
antigen
induct
potent
cellmedi
immun
respons
also
signific
implic
vlp
vaccin
diversifi
field
cover
broader
rang
disord
diseas
intracellular
process
pathway
remain
larg
unexplor
mani
vlp
elucid
underli
mechan
involv
advanc
applic
vlp
vaccin
gene
deliveri
immunomodul
role
formul
scienc
appear
underrepres
amongst
clinic
trial
clinic
report
vlp
vaccin
time
minim
elucid
vaccin
administr
rout
excipi
includ
even
exclus
adjuv
deliv
vaccin
import
formul
scienc
relev
excipi
adjuv
may
expectedli
underappreci
earlier
phase
research
develop
establish
vaccin
efficaci
may
paramount
howev
earli
adopt
vital
constitu
may
eas
clinic
translat
potenti
expand
repertoir
market
vlp
vaccin
novelti
proprietari
design
versatil
almost
import
develop
vlp
vaccin
actual
vaccin
efficaci
maintain
compat
upscal
product
gmp
manufactur
pipelin
anoth
import
compon
develop
vlp
vaccin
routin
clinic
administr
benefit
foresight
clear
promot
clinic
translat
advantag
across
field
vlp
vaccin
upon
review
across
field
includ
current
trend
new
emerg
research
progress
establish
vaccin
research
clinic
trial
schedul
vlp
vaccin
research
experienc
period
rapid
growth
includ
repertoir
organ
condit
target
vlp
vaccin
advanc
establish
vaccin
clinic
trial
translat
clinic
applic
next
five
year
predict
signific
increas
divers
vlp
vaccin
activ
circul
expect
vlp
use
complex
applic
vaccin
cognat
viru
deriv
also
predict
develop
novel
vlp
vaccin
construct
human
zoonot
pathogen
organ
condit
without
current
vaccin
option
incorpor
advanc
vaccin
methodolog
techniqu
routin
vlp
vaccin
product
distribut
administr
particular
predict
increas
incorpor
altern
vaccinestorag
techniqu
freezedri
spraydri
method
develop
vlp
vaccin
often
focus
facilit
distribut
amongst
popul
commun
vaccin
need
predict
next
five
year
capabl
support
vlp
vaccin
distribut
increas
limit
current
relianc
coldchain
deliveri
predict
outlin
excit
futur
next
five
year
vlp
vaccin
research
develop
viruslik
particl
consist
virusderiv
protein
associ
molecul
spontan
form
particul
structur
vlp
vaccin
safeti
profil
subunit
vaccin
efficaci
vaccin
outcom
compar
kill
live
attenu
vaccin
depend
particular
vlp
vaccin
predomin
desir
immun
respons
amongst
major
vlp
vaccin
potent
humor
respons
produc
high
titer
antibodi
vlp
vaccin
induc
potent
cytotox
immun
respons
select
elimin
cell
current
infect
target
viru
target
tumor
cell
formul
scienc
play
major
role
develop
vlp
vaccin
facilit
select
appropri
combin
excipi
adjuv
excipi
use
increas
vlp
particl
stabil
vaccin
formul
adjuv
enhanc
vaccin
efficaci
help
select
specif
desir
immun
respons
outcom
research
fund
univers
otago
interest
financi
conflict
subject
matter
materi
discuss
manuscript
apart
disclos
peer
review
manuscript
relev
financi
relationship
disclos
braeden
donaldson
http
vernon
k
ward
http
